Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07179003 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses
A Phase 2 study, sponsored by University of Rochester.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07179003 is a Phase 2 study that has not yet begun recruiting, run by University of Rochester. The registered enrollment target is 50 participants.
The verdict
NCT07179003, a Phase 2 study, has not yet begun recruiting, sponsored by University of Rochester.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. The investigators hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.
Interventions
- DRUG Methylene Blue
- DEVICE Insertion of optical fiber
- PROCEDURE Standard of care breast abscess drainage
- DRUG Lipid Emulsion
- DEVICE Laser illumination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04 |
| Est. Completion | 2031-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07179003
The ClinicalTrials.gov registry entry for NCT07179003 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methylene Blue is the first listed.
NCT07179003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07179003 about?
NCT07179003 is a clinical study titled "A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses". The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT...
What is the current status of trial NCT07179003?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-04. Estimated completion is 2031-03.
What interventions are being tested in trial NCT07179003?
The interventions under investigation include: Methylene Blue (DRUG), Insertion of optical fiber (DEVICE), Standard of care breast abscess drainage (PROCEDURE), Lipid Emulsion (DRUG), Laser illumination (DEVICE).
Who is sponsoring clinical trial NCT07179003?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.